Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

NCT04739072 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04739072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Observational
Overall status
Recruiting
Start date
November 22, 2019
Completion date
December 31, 2028
Enrollment
1,000 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, stage i colorectal cancer ajcc v8, stage ii colorectal cancer ajcc v8, stage iia colorectal cancer ajcc v8, stage iib colorectal cancer ajcc v8, stage iic colorectal cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v6, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8